Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Response Pharmaceuticals Initiates Phase 2 Trial Enrollment for New iMTP Inhibitor RDX-002 in Patients Discontinuing GLP-1 Agonists
Latest Hotspot
3 min read
Response Pharmaceuticals Initiates Phase 2 Trial Enrollment for New iMTP Inhibitor RDX-002 in Patients Discontinuing GLP-1 Agonists
22 October 2024
Response Pharmaceuticals has begun enrolling its first patients in a Phase 2 trial for RDX-002, a new small molecule iMTP inhibitor, targeting individuals stopping GLP-1 agonists.
Read →
Advancements in CMTX-101 Antibody Treatment for Cystic Fibrosis Infections Revealed by Clarametyx Biosciences
Latest Hotspot
4 min read
Advancements in CMTX-101 Antibody Treatment for Cystic Fibrosis Infections Revealed by Clarametyx Biosciences
22 October 2024
Clarametyx Biosciences reveals advancements in research on CMTX-101 antibody treatment for cystic fibrosis-related infections.
Read →
First Patient Dosed in Bright Peak's BPT567 Phase 1/2a Trial for PD1-IL18 Immunoconjugate
Latest Hotspot
3 min read
First Patient Dosed in Bright Peak's BPT567 Phase 1/2a Trial for PD1-IL18 Immunoconjugate
22 October 2024
Bright Peak Therapeutics has initiated dosing for the first patient in the Phase 1/2a clinical trial of BPT567, an innovative bifunctional PD1-IL18 immunoconjugate.
Read →
Wave Life Sciences Achieves First Successful Human RNA Editing in RestorAATion-2 Trial of WVE-006 for Alpha-1 Antitrypsin Deficiency
Latest Hotspot
4 min read
Wave Life Sciences Achieves First Successful Human RNA Editing in RestorAATion-2 Trial of WVE-006 for Alpha-1 Antitrypsin Deficiency
22 October 2024
Wave Life Sciences reports the first successful therapeutic RNA editing in humans during the RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency.
Read →
Latigo Biotherapeutics Initiates Phase 1 Trial of LTG-305 for Non-Opioid Pain Management
Latest Hotspot
3 min read
Latigo Biotherapeutics Initiates Phase 1 Trial of LTG-305 for Non-Opioid Pain Management
22 October 2024
Latigo Biotherapeutics has administered the first dose to a participant in its Phase 1 clinical trial for LTG-305, aimed at non-opioid pain management.
Read →
AI Empowers Small Nucleic Acid Drugs: New Strategies from Target Mining to Chemical Modification
Bio Sequence
14 min read
AI Empowers Small Nucleic Acid Drugs: New Strategies from Target Mining to Chemical Modification
22 October 2024
The role of Artificial Intelligence (AI) in the design of small nucleic acid drugs is becoming increasingly prominent.
Read →
Dosing Begins in IgGenix’s Phase 1 “ACCELERATE Peanut” Trial for Peanut Allergies
Latest Hotspot
3 min read
Dosing Begins in IgGenix’s Phase 1 “ACCELERATE Peanut” Trial for Peanut Allergies
18 October 2024
IgGenix has reported that the initial patient has been dosed in its Phase 1 trial, named "ACCELERATE Peanut," which is testing IGNX001 for peanut allergies.
Read →
How to find the structure and classification of Ravulizumab?
Bio Sequence
6 min read
How to find the structure and classification of Ravulizumab?
18 October 2024
Ravulizumab is composed of two types of polypeptide chains, light and heavy chains, which are typical of monoclonal antibodies.
Read →
Innovent Announces Success of Phase 2 Trial for Picankibart (IBI112) in Chinese Ulcerative Colitis Patients
Latest Hotspot
3 min read
Innovent Announces Success of Phase 2 Trial for Picankibart (IBI112) in Chinese Ulcerative Colitis Patients
18 October 2024
Innovent has revealed that its Phase 2 clinical trial of Picankibart (IBI112) in Chinese patients with ulcerative colitis has met its primary goal.
Read →
How to find the core components of mylotarg?
Bio Sequence
8 min read
How to find the core components of mylotarg?
18 October 2024
Structurally, mylotarg is characterized by its humanized IgG4 backbone, which contributes to its stability and reduced immunogenicity.
Read →
Alnylam Submits Vutrisiran Application to EMA for ATTR Amyloidosis with Cardiomyopathy
Latest Hotspot
3 min read
Alnylam Submits Vutrisiran Application to EMA for ATTR Amyloidosis with Cardiomyopathy
18 October 2024
Alnylam has filed a regulatory application with the European Medicines Agency for Vutrisiran aimed at treating ATTR amyloidosis with cardiomyopathy.
Read →
SciRhom Begins Administering Doses in First Human Trial for Its Main Development Project SR-878
Latest Hotspot
3 min read
SciRhom Begins Administering Doses in First Human Trial for Its Main Development Project SR-878
18 October 2024
SciRhom GmbH has announced the initiation of participant dosing in their first clinical trial for the advanced development program SR-878.
Read →